Saturday, August 30, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Jasper Therapeutics Presents Groundbreaking Preclinical Data on Briquilimabs Effectiveness in Preventing Allergic Reactions in Mice

Elaine Mendonca by Elaine Mendonca
February 5, 2024
in Breaking News
0
Biotechnology Trading online
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Jasper Therapeutics has announced that they will be presenting groundbreaking preclinical data on the effectiveness of Briquilimab, an anti-CD117 antibody, in preventing a wide range of allergic reactions in mice. The study specifically targets mice that express chimeric human and mouse CD117, and the results are highly promising.

The presentations will take place at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting on February 23-25, 2024. The details of each presentation are as follows:

1. Abstract Title: Briquilimab, An Anti-CD117 Antibody, Prevents Passive Systemic Anaphylaxis in Mice Expressing Chimeric Human and Mouse CD117 Through Mast Cell Depletion.
– Poster Number: 024
– Session Title: Therapeutic Trials in Allergic Skin Disorders and Anaphylaxis 2024
– Session Type: Poster Session
– Session Date / Time: Friday, February 23, 2024; 3:15 p.m. – 4:15 p.m. EST

2. Abstract Title: Briquilimab, an Anti-CD117 Antibody, Prevents Cockroach Allergen Induced Allergic Asthma in Mice Expressing Chimeric Human and Mouse CD117.
– Publication Number: 441
– Session Title: Old Therapeutics and New Targets in Asthma
– Session Type: Oral Abstract Session
– Session Date / Time: Saturday, February 24, 2024; 2:00 p.m. – 3:15 p.m. EST

3. Abstract Title: Amelioration Of Mrgprb2-Mediated Anaphylactoid Drug Reactions With Briquilimab, An Anti-CD117 Antibody, Through Mast Cell Depletion In Mice Expressing Chimeric Human And Mouse CD117.
– Poster Number: 747
– Session Title: Around the Horn: Dermatology, Drug Allergy, Anaphylaxis, Insect Hypersensitivity
– Session Type: Featured Poster Session
– Session Date / Time: Sunday, February 25, 2024; 4:45 p.m. – 6:15 p.m. EST

These presentations highlight the potential of Briquilimab in preventing various allergic reactions in mice, specifically targeting chimeric human and mouse CD117. The research conducted by Jasper Therapeutics may have significant implications for the development of therapeutics for allergic conditions in humans. Stay tuned for the groundbreaking findings from this study.

JSPR Stock Analysis: Mixed Performance and Stable Price Range on February 5, 2024

On February 5, 2024, JSPR stock exhibited mixed performance, with a slight drop during regular trading hours followed by a modest increase in after-hours trading. According to data from CNN Money, JSPR was trading in the middle of its 52-week range on that day, indicating that the stock price was relatively stable. JSPR was also trading above its 200-day simple moving average, which is a positive sign for investors. In terms of price change, JSPR shares experienced a decrease of $0.18 since the market last closed, representing a 1.47% drop. Despite the drop during regular trading hours, JSPR stock showed resilience in after-hours trading, rising by $0.47. Overall, investors should consider various factors to gain a more comprehensive understanding of JSPR’s performance and prospects.

JSPR Stock Performance: Analyzing Net Income and EPS Increase for Informed Investment Decisions

On February 5, 2024, investors eagerly awaited the stock performance of JSPR. JSPR reported a net income of -$37.69 million in the past year, representing a decrease of 23.0% compared to the previous year. JSPR’s EPS for the past year was reported at -$10.33, an increase of 61.59% compared to the previous year. However, it is essential to note that while the increase in EPS may seem promising, it should be interpreted with caution, considering the decline in net income. Investors and analysts would likely need more information, such as JSPR’s total revenue, to gain a comprehensive understanding of the company’s financial health and make informed investment decisions.

Tags: JSPR
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Healthcare Services Stock Exchange

Leadership Changes at Inspire Medical Systems Inc

Energy Company Markets and money

One Energy Enterprises Inc Welcomes Thomas Tom Russell as New CFO

Healthcare Services Stock Exchange

Oragenics Prepares for Groundbreaking Phase II Trials of ONP002 A Potential Breakthrough in Concussion Treatment

Recommended

Finance_Capitalization

The Security Implications of AI Adoption in the Banking Sector

2 years ago
Carlisle Stock

Carlisle Stock: Shares Tumble Despite Record Earnings

1 month ago
Finance_Credit

JP Morgan Downgrades Vir Biotechnologys Stock Rating and Price Target

2 years ago
Transportation Stock Bull Market

Bearish Indicators and Driver Strike Impact Lyfts Q4 Earnings

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

AAPL Adobe ADSK Alibaba AMD AMZN Apple AVGO BA Broadcom C Coinbase COST CRWD DIS DWAC Eli Lilly GM IBM INTC Intel Kraft Heinz LLY Lockheed META Micron MP Materials MSFT NFLX NIO NVO Opendoor Oracle Palantir PayPal PLTR Red Cat Robinhood Rocket Lab USA SMCI Strategy Tesla TGT Tilray TSLA
No Result
View All Result

Highlights

Insider Sales at Parke: A Contrarian Signal or Personal Portfolio Management?

Ziff Davis Stock Surges on Strong Quarterly Performance

iHeartMedia’s Digital Growth Offsets Legacy Radio Challenges

IBM Shares Slide Despite Strong Earnings as Software Unit Underperforms

A Tale of Two Signals: Insider Confidence Meets Analyst Caution at Civista Bancshares

Soleno Therapeutics: A Biotech Saga of Stellar Sales and Serious Allegations

Trending

Opendoor Stock
Analysis

Opendoor Shares Surge on Bullish Signals and Record Volume

by Robert Sasse
August 30, 2025
0

Opendoor Technologies Inc. (OPEN) experienced a dramatic trading session on Friday, characterized by significant volatility and a...

Cipher Mining Stock

Has Cipher Mining Stock Reached Its Peak?

August 30, 2025
Impinj Stock

Impinj Stock Surges: Can the RFID Leader Maintain Its Momentum After 50% Rally?

August 30, 2025
Parke Stock

Insider Sales at Parke: A Contrarian Signal or Personal Portfolio Management?

August 30, 2025
j2 Global Stock

Ziff Davis Stock Surges on Strong Quarterly Performance

August 30, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Recent News

  • Opendoor Shares Surge on Bullish Signals and Record Volume August 30, 2025
  • Has Cipher Mining Stock Reached Its Peak? August 30, 2025
  • Impinj Stock Surges: Can the RFID Leader Maintain Its Momentum After 50% Rally? August 30, 2025

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

© 2024 Stocks Today

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com